HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Pathologic Dilatation (Ectasia)

Subscribe to New Research on Pathologic Dilatation

The condition of an anatomical structure's being dilated beyond normal dimensions.

Also Known As:

Ectasia; Dilatation, Pathologic; Dilatation, Pathological; Dilatations, Pathologic; Dilatations, Pathological; Pathologic Dilatations; Pathological Dilatation; Pathological Dilatations

Networked: 604 relevant articles (25 outcomes, 25 trials/studies) for this Disease, Comments

Relationship Network

Disease Context: Research Results

Signs and Symptoms Pathological Conditions
- Anatomical Pathological Conditions
  - Pathologic Dilatation: 604

Related Diseases

1.	Astigmatism
2.	Hemorrhage
3.	Keratoconus
4.	Aneurysm (Aneurysms)
5.	Myopia

Experts

1.	Randleman, J Bradley: 13 articles (02/2009 - 02/2003)
2.	Stulting, R Doyle: 11 articles (12/2008 - 02/2003)
3.	Turhan, Hasan: 8 articles (09/2007 - 01/2004)
4.	Yetkin, Ertan: 8 articles (06/2007 - 01/2004)
5.	Kymionis, George D: 7 articles (02/2010 - 01/2002)
6.	Binder, Perry S: 7 articles (12/2008 - 12/2003)
7.	Aksoy, Yuksel: 6 articles (05/2007 - 02/2005)
8.	Alió, Jorge L: 5 articles (01/2010 - 11/2002)
9.	Erbay, Ali Riza: 5 articles (10/2009 - 11/2004)
10.	Epstein, Randy J: 5 articles (03/2009 - 03/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pathologic Dilatation:

1.	glucuronyl glucosamine glycan sulfate (Vessel)IBA 09/01/2007 - "According to the angiographic definition used in the Coronary Artery Surgery Study, a vessel is considered to be ectasic when its diameter is > or = 1.5 times that of the adjacent normal segment in segmental ectasia. " 02/01/2005 - "According to the angiographic definition used in the Coronary Artery Surgery Study, a vessel is considered to be ectasic when its diameter is > or =1.5 times that of the adjacent normal segment in segmental ectasia. " 01/01/2009 - "We found that all 18 cases were D2-40 positive, CD31 positive, and CD34 negative, suggesting the presence of nuchal lymph vessel ectasia. " 01/01/2009 - "[Coronary artery ectasia and triple-vessel disease]" 12/01/2008 - "Coronary ectasia involved a single vessel in 67.1%, two vessels in 24.9%, and three vessels in 8.1%, with the right coronary artery being the most common localization (50.9%). " Order ALL the reference details at left...
2.	ArgonIBA 04/01/2009 - "Efficacy of argon plasma coagulation in gastric vascular ectasia in patients with liver cirrhosis." 09/01/2008 - "The beneficial effects of argon plasma coagulation in the management of different types of gastric vascular ectasia lesions in patients admitted for GI hemorrhage." 06/01/2004 - "GI stromal tumor unmasked by argon plasma coagulation of vascular ectasia." 10/14/2007 - "Duodenal vascular ectasia may be a cause of upper gastrointestinal bleeding in patients with cirrhosis, and argon plasma coagulation may be effective and safe to achieve hemostasis of this lesion." 02/01/2008 - "Bleeding gastric vascular ectasia treated by argon plasma coagulation: a comparison between patients with and without cirrhosis." Order ALL the reference details at left...
3.	ElastinIBA 03/23/2004 - "MMP-9 or MMP-12 deficiency conferred significant protection against transmedial elastin degradation and ectasia in the atherosclerotic media. " 06/30/1999 - "at 50 mg/kg) had no effect on the extent of aortic atherosclerosis (36 +/- 4% versus 30 +/- 2% in controls), but both aortic medial elastin destruction and ectasia grade were significantly reduced (38% and 36%, respectively, p < 0.05). " 07/16/1982 - "These findings point to a change in the structure or metabolism of elastin in the aortic wall in the Marfan syndrome and at least in some other patients with annulo-aortic ectasia." 11/15/1985 - "Aortic samples from patients with annulo-aortic ectasia (aneurysm of the ascending aorta), including one with classical Marfan syndrome, contained less elastin (CNBr-insoluble material) than did the age-matched controls. " 01/01/2007 - "The elastic lamellae undergo fragmentation and thinning, leading to ectasia and a gradual transfer of mechanical load to collagen, which is 100-1000 times stiffer than elastin. " Order ALL the reference details at left...
4.	Mitomycin (Mitomycin-C)FDA LinkGeneric 05/01/1999 - "Corneal ectasia after trabeculectomy with mitomycin C application." 01/01/2006 - "Adjunctive utilization of intraoperative low-dose 0.02% mitomycin C for the management of chronic uveitic glaucoma patients who are under concomitant systemic immunosuppressive regimen may enhance the risk of subacute postoperative sclerolimbal ectasia. " 01/01/2006 - "A case of early-onset sclerolimbal ectasia following low-dose topical mitomycin C application during uveitic glaucoma surgery is reported. " Order ALL the reference details at left...
5.	Estrogens (Estrogen)FDA Link 04/15/1989 - "[Estrogen therapy in digestive hemorrhage caused by diffuse vascular ectasia of the gastric antrum]" 12/01/2005 - "Urgent aortic valve replacement (AVR) was performed after preoperative hormonal (estrogen-progesterone) therapy, that might be effective for bleeding from vascular ectasia. " Order ALL the reference details at left...
6.	CreatinineIBA 07/01/1991 - "In 51 cases the orchiectomy was combined with transurethral resection of the prostate (TURP); 37 patients had pathological levels of serum creatinine and 17 had pathological dilatation of the upper urinary tract, 6 of whom required a nephrostomy catheter. " 02/01/2009 - "Surgical POP repair resolved the prolapse all patients and cured the ureterohydronephrosis in 7, with moderate ectasia of the upper urinary tract persisting in 2. The renal function at diagnosis was normal in 12 of 13 patients with hydronephrosis (mean 113 +/- 15 micromol/L); 1 patient had a high serum creatinine concentration (220 micromol/L). " Order ALL the reference details at left...
7.	ThiazidesIBA 05/01/1978 - "3) Thiazides are effective in normocalciuric as well as hypercalciuric patients and in most patients with tubular ectasia (medullary sponge kidney). " Order ALL the reference details at left...
8.	Progesterone FDA LinkGeneric 12/01/2005 - "Urgent aortic valve replacement (AVR) was performed after preoperative hormonal (estrogen-progesterone) therapy, that might be effective for bleeding from vascular ectasia. " Order ALL the reference details at left...
9.	Phenobarbital (Luminal)FDA Link 10/01/2009 - "Coronary artery ectasia was defined as a luminal dilatation of at least 1.5 times of the adjacent normal coronary segments, without any stenotic lesions. " 08/01/2007 - "Coronary artery ectasia was defined as without any stenotic lesion, on visual assessment, of the coronary arteries with a luminal dilatation 1.5-fold or more of the adjacent normal coronary segments. " 06/01/2007 - "Coronary artery ectasia (CAE) is defined as a localized or diffuse non-obstructive lesion of the epicardial coronary arteries with a luminal dilation exceeding 1.5-fold the diameter of the normal adjacent arterial segment. " 01/01/2004 - "Coronary artery ectasia was defined as nonobstructive lesions of the coronary arteries with a luminal dilatation 1.5-fold or more of the adjacent normal coronary segments. " 01/01/1987 - "The study of the first local excision leads to the thought of a "duct ectasia with a luminal benign papilloma". " Order ALL the reference details at left...
10.	Matrix MetalloproteinasesIBA 12/01/2008 - "Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia." 04/01/2005 - "We hypothesized that dysregulation of circulating matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs) contributes to ectasia formation. " 12/01/1999 - "Coronary ectasia in familial hypercholesterolemia: histopathologic study regarding matrix metalloproteinases." 03/23/2004 - "In addition, deficiency of MMP-9 or MMP-12 protected apolipoprotein E-deficient mice against atherosclerotic media destruction and ectasia, mechanisms that implicate the involvement of these MMPs in aneurysm formation." Order ALL the reference details at left...

Therapies and Procedures

1.	Laser In Situ Keratomileusis (LASIK) 03/01/2003 - "CONCLUSIONS: Intracorneal ring segments implantation improved uncorrected visual acuity and best spectacle-corrected visual acuity in patients with post-LASIK ectasia. " 05/01/2008 - "CONCLUSIONS: The Ectasia Risk Score System is a valid and effective method for detecting eyes at risk for ectasia after LASIK and represents a significant improvement over previously utilized screening strategies." 01/01/2008 - "CONCLUSIONS: A quantitative method can be used to identify eyes at risk for developing ectasia after LASIK that, if validated, represents a significant improvement over current screening strategies." 09/01/2002 - "When used in combination with videokeratography, the Orbscan II topography system may be helpful in identifying patients who are potentially at high risk for developing ectasia after LASIK." 01/01/2002 - "CONCLUSION: Implantation of INTACS in eyes with corneal ectasia after LASIK resulted in good refractive outcome, absence of complications, and improvement in visual acuity." Order ALL the reference details at left...
2.	Prostheses and Implants (Prosthesis) 10/01/2000 - "Clinical introduction of a novel prosthesis for valve-preserving aortic root reconstruction for annuloaortic ectasia." 11/01/1979 - "Two patients had infected aortic valve prostheses, three patients had acute aortic dissection and three had annuloaortic ectasia. " 01/01/2010 - "CONCLUSIONS: The Boston Ocular Surface Prosthesis significantly improved VA and visual functioning in patients with corneal ectasia, irregular astigmatism, and ocular surface disease who had failed conventional therapies." 12/01/2009 - "Assuming that benefits persist for an average of 5 years, the lifetime gain was 0.48 QALYs; the average cost-effectiveness of the prosthesis was $24,900 per QALY (95% confidence interval $19,100 to $29,600), and the average benefit-cost ratio was 4.0 to 1. In patients with the lowest baseline scores (average VFQ score 38.6), results were even more favorable: cost-effectiveness $17,100 per QALY and benefit-cost ratio 5.6 to 1. CONCLUSIONS: The Boston Ocular Surface Prosthesis is cost-effective and cost beneficial in patients with severely compromised visual function attributable to ectasia, irregular astigmatism, or ocular surface disease." 01/01/2010 - "METHODS: The study examined the effects of this prosthesis on VA and visual functioning in consecutive patients with corneal ectasia, irregular astigmatism, or ocular surface disease who had failed conventional therapies and were seen at the Boston Foundation for Sight between January 1 and June 30, 2006. " Order ALL the reference details at left...
3.	Penetrating Keratoplasty 03/01/2007 - "Penetrating keratoplasty versus intrastromal corneal ring segments to correct bilateral corneal ectasia: preliminary study." 07/01/2007 - "SUMMARY: These new forms of surgery are viable alternatives to conventional penetrating keratoplasty and bring added safety profiles for long-term visual rehabilitation and restoration of tectonic integrity in central and peripheral forms of corneal ectasia." 03/01/2007 - "PURPOSE: To describe the outcomes over time in patients with corneal ectasia pathology treated with intrastromal corneal ring segments (Intacs, Addition Technology, Inc.) in 1 eye and penetrating keratoplasty (PKP) in the other eye. " 09/01/2002 - "In the short term, these techniques seem to be helpful in reducing the progression of corneal ectasia after excimer laser surgery, delaying or avoiding the need of penetrating keratoplasty." 08/01/2009 - "PURPOSE: To evaluate the healing response at the flap interface in corneas with LASIK ectasia that required penetrating keratoplasty (PK). " Order ALL the reference details at left...
4.	Transplants (Transplant) 02/01/2009 - "Ectasia was often preceded by thinning without bulging of the recipient stroma at the graft-host junction. " 09/01/2006 - "The suturing of a corneoscleral graft over a severely ectatic cornea may be an acceptable technique for providing tectonic tissue support and stabilizing eyes with severe anterior segment ectasia." 09/01/2006 - "Three months postoperatively, the graft was stable with no progression of the ectasia. " 04/01/2003 - "Common iliac artery ectasia and aneurysmal disease has become another indication for use of the AneuRx commercial graft at our institution, with no significant differences in intermediate outcome. " 02/01/1998 - "A 31-year-old man with type A chronic aortic dissection associated with annuloaortic ectasia underwent the concomitant graft replacement of the total aortic root and the transverse aortic arch. " Order ALL the reference details at left...
5.	Excimer Lasers 08/01/2009 - "METHODS: Patients with corneal ectasia were treated with superficial corneal epithelial removal using the excimer laser programmed to 35 mum of phototherapeutic keratectomy (Group 1) or mechanical full-thickness epithelial removal with a brush (Group 2). " 12/01/2008 - "Corneal ectasia after excimer laser keratorefractive surgery: histopathology, ultrastructure, and pathophysiology." 09/01/2002 - "In the short term, these techniques seem to be helpful in reducing the progression of corneal ectasia after excimer laser surgery, delaying or avoiding the need of penetrating keratoplasty." 01/01/2008 - "PURPOSE: To analyze the epidemiologic features of ectasia after excimer laser corneal refractive surgery, to identify risk factors for its development, and to devise a screening strategy to minimize its occurrence. " 08/01/2006 - "PURPOSE: To describe the clinical and ultrastructural features of a prominent ectasia of the cornea that occurred 9 years after excimer laser photorefractive keratectomy (PRK). " Order ALL the reference details at left...

blog comments powered by Disqus

TREATMENT OPTIONS
for Pathologic Dilatation,
Ranking and Evidence

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 25 Outcomes
Top 193 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>